Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Treasury Shares (2021 - 2025)

Fennec Pharmaceuticals filings provide 5 years of Treasury Shares readings, the most recent being $387000.0 for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 19.44% to $387000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $387000.0, a 19.44% increase, with the full-year FY2025 number at $387000.0, up 19.44% from a year prior.
  • Treasury Shares hit $387000.0 in Q4 2025 for Fennec Pharmaceuticals, down from $419000.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $589000.0 in Q1 2025 to a low of $35000.0 in Q4 2022.
  • Median Treasury Shares over the past 5 years was $219000.0 (2021), compared with a mean of $248315.8.
  • Biggest five-year swings in Treasury Shares: crashed 84.02% in 2022 and later soared 522.86% in 2023.
  • Fennec Pharmaceuticals' Treasury Shares stood at $219000.0 in 2021, then crashed by 84.02% to $35000.0 in 2022, then soared by 522.86% to $218000.0 in 2023, then soared by 48.62% to $324000.0 in 2024, then increased by 19.44% to $387000.0 in 2025.
  • The last three reported values for Treasury Shares were $387000.0 (Q4 2025), $419000.0 (Q3 2025), and $100000.0 (Q2 2025) per Business Quant data.